243 related articles for article (PubMed ID: 29185395)
1. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.
Javed A; Arguello D; Johnston C; Gatalica Z; Terai M; Weight RM; Orloff M; Mastrangelo MJ; Sato T
Immunotherapy; 2017 Dec; 9(16):1323-1330. PubMed ID: 29185395
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.
Singh L; Singh MK; Kenney MC; Jager MJ; Rizvi MA; Meel R; Lomi N; Bakhshi S; Sen S; Kashyap S
Cancer Immunol Immunother; 2021 May; 70(5):1291-1303. PubMed ID: 33136179
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis.
Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G
Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma.
Zoroquiain P; Esposito E; Logan P; Aldrees S; Dias AB; Mansure JJ; Santapau D; Garcia C; Saornil MA; Belfort Neto R; Burnier MN
Mod Pathol; 2018 Aug; 31(8):1201-1210. PubMed ID: 29581543
[TBL] [Abstract][Full Text] [Related]
7. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
[TBL] [Abstract][Full Text] [Related]
8. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
9. Melanoma subtypes demonstrate distinct PD-L1 expression profiles.
Kaunitz GJ; Cottrell TR; Lilo M; Muthappan V; Esandrio J; Berry S; Xu H; Ogurtsova A; Anders RA; Fischer AH; Kraft S; Gerstenblith MR; Thompson CL; Honda K; Cuda JD; Eberhart CG; Handa JT; Lipson EJ; Taube JM
Lab Invest; 2017 Sep; 97(9):1063-1071. PubMed ID: 28737763
[TBL] [Abstract][Full Text] [Related]
10. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
11. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Madore J; Vilain RE; Menzies AM; Kakavand H; Wilmott JS; Hyman J; Yearley JH; Kefford RF; Thompson JF; Long GV; Hersey P; Scolyer RA
Pigment Cell Melanoma Res; 2015 May; 28(3):245-53. PubMed ID: 25477049
[TBL] [Abstract][Full Text] [Related]
14. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Kluger HM; Zito CR; Barr ML; Baine MK; Chiang VL; Sznol M; Rimm DL; Chen L; Jilaveanu LB
Clin Cancer Res; 2015 Jul; 21(13):3052-60. PubMed ID: 25788491
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.
Madore J; Strbenac D; Vilain R; Menzies AM; Yang JY; Thompson JF; Long GV; Mann GJ; Scolyer RA; Wilmott JS
Clin Cancer Res; 2016 Aug; 22(15):3915-23. PubMed ID: 26960397
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
[No Abstract] [Full Text] [Related]
17. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.
Yang W; Chen PW; Li H; Alizadeh H; Niederkorn JY
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2518-25. PubMed ID: 18296654
[TBL] [Abstract][Full Text] [Related]
18. Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy.
López MN; Pereda C; Ramírez M; Mendoza-Naranjo A; Serrano A; Ferreira A; Poblete R; Kalergis AM; Kiessling R; Salazar-Onfray F
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1219-27. PubMed ID: 17325166
[TBL] [Abstract][Full Text] [Related]
19. Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas.
Săftescu S; Munteanu M; Popovici D; Dragomir R; Negru AG; Pac PC; Negru ȘM
Rom J Ophthalmol; 2020; 64(2):184-189. PubMed ID: 32685785
[TBL] [Abstract][Full Text] [Related]
20. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Bertrand F; Montfort A; Marcheteau E; Imbert C; Gilhodes J; Filleron T; Rochaix P; Andrieu-Abadie N; Levade T; Meyer N; Colacios C; Ségui B
Nat Commun; 2017 Dec; 8(1):2256. PubMed ID: 29273790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
